دورية أكاديمية
[Response of Pharmaceutical Companies to the Crisis of Post-Marketing Clinical Trials of Anti-Cancer Agents -- Results of Questionnaires to Pharmaceutical Companies].
| العنوان: | [Response of Pharmaceutical Companies to the Crisis of Post-Marketing Clinical Trials of Anti-Cancer Agents -- Results of Questionnaires to Pharmaceutical Companies]. |
|---|---|
| المؤلفون: | Nakajima T; Vice Director, Japan Clinical Cancer Research Organization, Consulting Doctor, Japanese Foundation for Cancer Research. |
| المصدر: | Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2016 Apr; Vol. 43 (4), pp. 486-9. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Japanese |
| بيانات الدورية: | Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tokyo : Gan To Kagaku Ryohosha Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]- |
| مواضيع طبية MeSH: | Clinical Trials as Topic* , Drug Industry* , Neoplasms*/drug therapy, Antineoplastic Agents/*therapeutic use, Antineoplastic Agents/economics ; Humans ; Marketing of Health Services ; Surveys and Questionnaires |
| مستخلص: | Investigator-oriented post-marketing clinical trials of anti-cancer agents are faced to financial crisis due to drastic decrease in research-funds from pharmaceutical companies caused by a scandal in 2013. In order to assess the balance of research funds between 2012 and 2014, we made queries to 26 companies manufacturing anti-cancer agents, and only 10 of 26 responded to our queries. Decrease in the fund was observed in 5 of 10, no change in 1, increase in 3 and no answer in 1. Companies showed passive attitude to carry out doctor-oriented clinical trials of off-patent drugs or unapproved drugs according to advanced medical care B program, though some companies answered to proceed approved routines of these drugs if clinical trials showed good results. Most companies declined to make comments on the activity of Japan Agency for Medical Research and Development (AMED), but some insisted to produce good corroboration between AMED and pharmaceutical companies in order to improve the quality of trials. Further corroboration must be necessary for this purpose among researchers, governmental administrative organs, pharmaceutical companies, patients' groups, and mass-media. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20160526 Date Completed: 20160613 Latest Revision: 20160525 |
| رمز التحديث: | 20240829 |
| PMID: | 27220801 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0385-0684 |
|---|